AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36158129 — intervention group
Group type: COMPARATOR
Intervention: Non Hp-infected gastric cancer patients (comparison group)
Number of subjects: 100
Study 32359393 — intervention group
Group type: EXPERIMENTAL
Intervention: Qing Qiao Capsule
Number of subjects: 100
Study 32359393 — intervention group
Group type: COMPARATOR
Intervention: Caefaclor capsule (Control)
Number of subjects: 100
Study 35661157 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant ipilimumab 1 mg kg−1 and nivolumab 3 mg kg−1 for 6 weeks
Number of subjects: 99
Study 35661157 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic lymph node dissection (TLND) omitted in patients with MPR
Number of subjects: 99
Study 35661157 — intervention group
Group type: EXPERIMENTAL
Intervention: TLND only for patients with pathologic partial response (pPR)
Number of subjects: 99
Study 35661157 — intervention group
Group type: EXPERIMENTAL
Intervention: TLND and adjuvant systemic therapy ± synchronous radiotherapy for patients with pathologic non-response (pNR)
Number of subjects: 99
Study 35661157 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 3–4 toxicity within the first 12 weeks
Number of subjects: 99
Study 33957336 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine (15 mg)
Number of subjects: 15
Study 33957336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 35001439 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma (CP) administration as a complement to standard treatment
Number of subjects: 0
Study 35001439 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment plus non-convalescent plasma (control)
Number of subjects: 0
Study 35904750 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (acetyl-salicylic acid plus a P2Y12 inhibitor)
Number of subjects: 60
Study 35904750 — intervention group
Group type: COMPARATOR
Intervention: Antiplatelet monotherapy (a P2Y12 inhibitor) plus low dose anticoagulant (rivaroxaban, 15mg oral dose)
Number of subjects: 60
Study 32927668 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g per day of cocoa-rich chocolate (99%) for 6 months
Number of subjects: 140
Study 36217289 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabbit Anti-Thymocyte Globulin (rATG) 5 mg/kg from days -5 to -2
Number of subjects: 85
Study 36217289 — intervention group
Group type: COMPARATOR
Intervention: Non-ATG
Number of subjects: 85
Study 36217289 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabbit Anti-Thymocyte Globulin (rATG)
Number of subjects: 85
Study 33715931 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot reflexology for an average of 20 min before heel lance
Number of subjects: 60
Study 33715931 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot reflexology
Number of subjects: 60
Study 33715931 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 60
Study 35469478 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg diclofenac sodium
Number of subjects: 122
Study 35469478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 33333285 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (10 mg, qd, from the first day postoperatively, for 2 weeks)
Number of subjects: 49
Study 33333285 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine analgesic regimens including injection of cocktail mixture intraoperatively, oral celecoxib and tramadol postoperatively)
Number of subjects: 49
Study 33977506 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 12.5 mg orally every 12 h for 10 days plus standard of care (SOC)
Number of subjects: 31
Study 33977506 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) alone
Number of subjects: 31
Study 32114516 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) and optimal medical therapy (OMT)
Number of subjects: 104
Study 32114516 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy (OMT)
Number of subjects: 104
Study 35959805 — intervention group
Group type: EXPERIMENTAL
Intervention: UCB0599
Number of subjects: 31
Study 35959805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 33978130 — intervention group
Group type: EXPERIMENTAL
Intervention: New Moves program (participation in 1 to 9 sessions)
Number of subjects: 270
Study 33978130 — intervention group
Group type: EXPERIMENTAL
Intervention: New Moves program (participation in 10 to 17 sessions)
Number of subjects: 270
Study 33978130 — intervention group
Group type: EXPERIMENTAL
Intervention: New Moves program
Number of subjects: 270
Study 33295977 — intervention group
Group type: EXPERIMENTAL
Intervention: Burnout (measured using subscales of the Stanford Professional Fulfillment Index, Maslach Burnout Inventory‐Human Services Survey for Medical Personnel, and Mini‐Z burnout survey)
Number of subjects: 1354
Study 33295977 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression (measured using the Patient‐Reported Outcomes Measurement Information System depression Short Form)
Number of subjects: 1354
Study 33295977 — intervention group
Group type: EXPERIMENTAL
Intervention: Burnout
Number of subjects: 1354
Study 33295977 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 1354
Study 36218286 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart Beginnings (SB) intervention
Number of subjects: 0
Study 36218286 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 34304069 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater Occipital Nerve (GON) block with 1% lidocaine
Number of subjects: 128
Study 34304069 — intervention group
Group type: EXPERIMENTAL
Intervention: Supra Orbital Nerve (SON) block with 1% lidocaine
Number of subjects: 128
Study 34304069 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined GON and SON block with 1% lidocaine
Number of subjects: 128
Study 34304069 — intervention group
Group type: COMPARATOR
Intervention: Placebo with 0.9% NaCl
Number of subjects: 128
Study 36398542 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 800 IU/d (subgroup A)
Number of subjects: 161
Study 36398542 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized vitamin D3 supplementation (subgroup B)
Number of subjects: 161
Study 36398542 — intervention group
Group type: COMPARATOR
Intervention: Sufficiency group
Number of subjects: 161
Study 36398542 — intervention group
Group type: COMPARATOR
Intervention: Deficiency group
Number of subjects: 161
Study 33268434 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic polypectomy performed in clinic (EPIC)
Number of subjects: 140
Study 33268434 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 140
Study 34283529 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurouridin dietary supplement
Number of subjects: 3179
Study 34283529 — intervention group
Group type: COMPARATOR
Intervention: Control group (no neurouridin)
Number of subjects: 3179
Study 32105112 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent Treatment of PTSD and Substance Use Disorder Using Prolonged Exposure (COPE)
Number of subjects: 107
Study 32105112 — intervention group
Group type: COMPARATOR
Intervention: Seeking Safety (SS)
Number of subjects: 107
Study 34981420 — intervention group
Group type: EXPERIMENTAL
Intervention: IV norepinephrine + oral midodrine 10 mg thrice a day
Number of subjects: 60
Study 34981420 — intervention group
Group type: COMPARATOR
Intervention: IV norepinephrine
Number of subjects: 60
Study 34106626 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl cellulose soluble hemostatic gauze
Number of subjects: 282
Study 34106626 — intervention group
Group type: COMPARATOR
Intervention: Sterile gauze
Number of subjects: 282
Study 35316858 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy along with conscious sedation (Group A)
Number of subjects: 109
Study 35316858 — intervention group
Group type: COMPARATOR
Intervention: Conscious sedation alone (Group B)
Number of subjects: 109
Study 32098012 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane-based anesthesia (volatile anesthetic)
Number of subjects: 20
Study 32098012 — intervention group
Group type: COMPARATOR
Intervention: Propofol-based anesthesia (intravenous anesthetic)
Number of subjects: 20
Study 33566466 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 568
Study 33566466 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline
Number of subjects: 568
Study 33566466 — intervention group
Group type: COMPARATOR
Intervention: Control group (no osmotherapy)
Number of subjects: 568
Study 32512710 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of porcine placenta extract once daily for 4 weeks
Number of subjects: 20
Study 32512710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 34191034 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Maxillary Expansion (RME) protocol
Number of subjects: 36
Study 34191034 — intervention group
Group type: COMPARATOR
Intervention: Alternating Rapid Maxillary Expansion and Constriction (Alt‐RAMEC) protocol
Number of subjects: 36
Study 34191034 — intervention group
Group type: COMPARATOR
Intervention: Comparison of RME and Alt‐RAMEC groups
Number of subjects: 36
Study 34191034 — intervention group
Group type: COMPARATOR
Intervention: Age and sex relationship with STT
Number of subjects: 36
Study 34863192 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive (30% incentive for fruits and vegetables purchased with study benefits)
Number of subjects: 249
Study 34863192 — intervention group
Group type: EXPERIMENTAL
Intervention: Restriction (not allowed to buy sugar-sweetened beverages, sweet baked goods, or candy using study benefits)
Number of subjects: 249
Study 34863192 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive plus restriction
Number of subjects: 249
Study 34863192 — intervention group
Group type: COMPARATOR
Intervention: Control (no incentive or restriction)
Number of subjects: 249
Study 32278421 — intervention group
Group type: EXPERIMENTAL
Intervention: Near infrared spectroscopy using lyophilized wine samples
Number of subjects: 0
Study 616172503 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP guided therapy (group 1)
Number of subjects: 105
Study 616172503 — intervention group
Group type: COMPARATOR
Intervention: Standard heart failure therapy (group 2)
Number of subjects: 105
Study 34726348 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange (PE) with albumin replacement
Number of subjects: 347
Study 34726348 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham-PE)
Number of subjects: 347
Study 33257214 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete revascularization (ComR)
Number of subjects: 306
Study 33257214 — intervention group
Group type: COMPARATOR
Intervention: Selective stress echocardiography-guided revascularization (SelR)
Number of subjects: 306
Study 35861908 — intervention group
Group type: EXPERIMENTAL
Intervention: Class IIa medical device containing lactic acid, azelaic acid/polyglyceryl‐3 copolymer, azelamidopropyl dimethyl amine, and bifida ferment lysate, used twice daily for 2 months
Number of subjects: 60
Study 35861908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 33840781 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagenase clostridium histolyticum‐aaes (CCH) 0.84 mg
Number of subjects: 843
Study 33840781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 843
Study 35343453 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hygiene instructions (OHI)
Number of subjects: 64
Study 35343453 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage full-mouth scaling and root planning (SRP) combining OHI
Number of subjects: 64
Study 33346847 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring (n=147) including wearable activity monitor, messaging about postoperative goals, pain score tracking, and connection to clinicians.
Number of subjects: 242
Study 33346847 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=153)
Number of subjects: 242
Study 33346847 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring with gamification and social support
Number of subjects: 242
Study 33346847 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring (n=147)
Number of subjects: 242
Study 34265576 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantago major seed (3600 mg/day)
Number of subjects: 61
Study 34265576 — intervention group
Group type: COMPARATOR
Intervention: Roasted wheat flour (control)
Number of subjects: 61
Study 34478564 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar energy (Group 1)
Number of subjects: 84
Study 34478564 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemostatic sealants (Group 2)
Number of subjects: 84
Study 34478564 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture (Group 3)
Number of subjects: 84
Study 34478564 — intervention group
Group type: COMPARATOR
Intervention: All groups (Bipolar energy, Hemostatic sealants, Suture)
Number of subjects: 84
Study 33499861 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of flesh foods
Number of subjects: 1517
Study 33499861 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of eggs
Number of subjects: 1517
Study 33499861 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal frequency of three times or more per day
Number of subjects: 1517
Study 33499861 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater than mild pubertal development in males
Number of subjects: 1517
Study 33499861 — intervention group
Group type: COMPARATOR
Intervention: Female adolescents compared to males
Number of subjects: 1517
Study 33499861 — intervention group
Group type: COMPARATOR
Intervention: Mothers with completed high school education compared to <3 years of formal education
Number of subjects: 1517
Study 33334195 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol tablets with red propolis (XPT)
Number of subjects: 0
Study 33334195 — intervention group
Group type: COMPARATOR
Intervention: Xylitol tablets without red propolis (XT)
Number of subjects: 0
Study 34233059 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect questioning technique
Number of subjects: 1366
Study 34233059 — intervention group
Group type: COMPARATOR
Intervention: Direct questioning technique
Number of subjects: 1366
Study 32102629 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 0
Study 32102629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35584324 — intervention group
Group type: EXPERIMENTAL
Intervention: HP35ca (bleached using 35% hydrogen peroxide with Ca)
Number of subjects: 60
Study 35584324 — intervention group
Group type: EXPERIMENTAL
Intervention: HP35wca (bleached using 35% hydrogen peroxide without Ca)
Number of subjects: 60
Study 35584324 — intervention group
Group type: COMPARATOR
Intervention: Control (without bleaching)
Number of subjects: 60
Study 33596885 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime sleepiness (Epworth Sleepiness Scale - ESS)
Number of subjects: 1350
Study 33596885 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower ESS scores
Number of subjects: 1350
Study 33596885 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Number of subjects: 1350
Study 35362336 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic treatment for 6 months
Number of subjects: 0
Study 35362336 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 32689628 — intervention group
Group type: EXPERIMENTAL
Intervention: GEAR
Number of subjects: 19
Study 32689628 — intervention group
Group type: COMPARATOR
Intervention: Treadmill
Number of subjects: 19
Study 33772845 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide infusion
Number of subjects: 36
Study 33772845 — intervention group
Group type: COMPARATOR
Intervention: CGRP infusion
Number of subjects: 36
Study 36479786 — intervention group
Group type: EXPERIMENTAL
Intervention: Early glargine group (subcutaneous insulin glargine 0.3 units/kg within the first 3 hours of DKA diagnosis, in addition to standard IV insulin infusion)
Number of subjects: 60
Study 36479786 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard IV insulin treatment only)
Number of subjects: 60
Study 36479786 — intervention group
Group type: EXPERIMENTAL
Intervention: Early glargine group
Number of subjects: 60
Study 36479786 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 36479786 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 34735099 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 113
Study 34735099 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine extended release
Number of subjects: 113
Study 32930090 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching to an equivalent dose of quetiapine, aripiprazole, or olanzapine with brief psychoeducation and support.
Number of subjects: 98
Study 32930090 — intervention group
Group type: COMPARATOR
Intervention: Enhanced standard care alone.
Number of subjects: 98
Study 33533074 — intervention group
Group type: EXPERIMENTAL
Intervention: Melasolv™ applied twice a day for 12 weeks
Number of subjects: 0
Study 33533074 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied twice a day for 12 weeks
Number of subjects: 0
Study 33533074 — intervention group
Group type: EXPERIMENTAL
Intervention: Melasolv™
Number of subjects: 0
Study 33533074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32697485 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure guided by electrical impedance tomography (PEEPEIT)
Number of subjects: 20
Study 32697485 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive end-expiratory transpulmonary pressure (PEEPPL)
Number of subjects: 20
Study 32697485 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEPEIT
Number of subjects: 20
Study 32697485 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEPPL
Number of subjects: 20
Study 35103605 — intervention group
Group type: EXPERIMENTAL
Intervention: MyCourse (digital alcohol moderation intervention)
Number of subjects: 103
Study 35103605 — intervention group
Group type: COMPARATOR
Intervention: Control (noninteractive digital information brochure)
Number of subjects: 103
Study 35103605 — intervention group
Group type: EXPERIMENTAL
Intervention: MyCourse
Number of subjects: 103
Study 35103605 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 103
Study 34787294 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic drainage (AD) plus routine chest physiotherapy
Number of subjects: 48
Study 34787294 — intervention group
Group type: COMPARATOR
Intervention: Routine chest physiotherapy only
Number of subjects: 48
Study 34699618 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide 1,500 mg orally twice-daily with food for 7 days
Number of subjects: 14
Study 32493500 — intervention group
Group type: EXPERIMENTAL
Intervention: CAREDYNE Shield
Number of subjects: 40
Study 32493500 — intervention group
Group type: COMPARATOR
Intervention: Nanoseal
Number of subjects: 40
Study 33771722 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate 80 μg via Breezhaler® (low-dose ICS)
Number of subjects: 96
Study 33771722 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate 320 μg via Breezhaler® (high-dose ICS)
Number of subjects: 96
Study 33771722 — intervention group
Group type: COMPARATOR
Intervention: Mometasone furoate via Breezhaler® (50-400 μg)
Number of subjects: 96
Study 33771722 — intervention group
Group type: COMPARATOR
Intervention: Mometasone furoate via Twisthaler® (200 μg and 800 μg)
Number of subjects: 96
Study 32429874 — intervention group
Group type: EXPERIMENTAL
Intervention: Less invasive surfactant administration via nasal route (LISA-n)
Number of subjects: 20
Study 36253574 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive virtual classroom training (VCT) with the FRS curriculum
Number of subjects: 11
Study 36253574 — intervention group
Group type: COMPARATOR
Intervention: Fundamentals of Robotic Surgery (FRS) curriculum only
Number of subjects: 11
Study 36253574 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive virtual classroom training (VCT) after initial training with FRS curriculum
Number of subjects: 11
Study 36253574 — intervention group
Group type: COMPARATOR
Intervention: Fundamentals of Robotic Surgery (FRS) curriculum only (after receiving VCT)
Number of subjects: 11
Study 36378836 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineal electrical stimulation (ES), 3 days a week, 20 min a day, for 8 weeks (total of 24 sessions)
Number of subjects: 58
Study 36378836 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control Group)
Number of subjects: 58
Study 34237457 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment and retention strategies
Number of subjects: 157
Study 32650155 — intervention group
Group type: EXPERIMENTAL
Intervention: Land-based exercise training (LET)
Number of subjects: 53
Study 32650155 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based exercise training (WET)
Number of subjects: 53
Study 32650155 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 53
Study 36235546 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced parenteral nutrition (higher glucose infusion rate and intralipids)
Number of subjects: 90
Study 36235546 — intervention group
Group type: COMPARATOR
Intervention: Standard parenteral nutrition
Number of subjects: 90
Study 36235546 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced parenteral nutrition
Number of subjects: 90
Study 36235546 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher enteral energy and protein intake (regardless of randomization group)
Number of subjects: 90
Study 34090212 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized nutritional support to reach specific protein and energy goals
Number of subjects: 881
Study 34090212 — intervention group
Group type: COMPARATOR
Intervention: Routine hospital food
Number of subjects: 881
Study 34090212 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized nutritional support
Number of subjects: 881
Study 32801649 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of amitriptyline hydrochloride (25 mg)
Number of subjects: 24
Study 32801649 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of amitriptyline hydrochloride (25 mg)
Number of subjects: 24